4.7 Article

SOX2 as a novel contributor of oxidative metabolism in melanoma cells

Journal

CELL COMMUNICATION AND SIGNALING
Volume 16, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/s12964-018-0297-z

Keywords

Melanoma; Tumor extracellular acidosis; SOX2; HIF1 alpha; Oxidative metabolism

Categories

Funding

  1. Istituto Toscano Tumori (ITT) (Decreto Dirigenziale Regione Toscana) [5254]
  2. Ente Cassa di Risparmio di Firenze, Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG-14184]
  3. Universita degli Studi di Firenze

Ask authors/readers for more resources

BackgroundDeregulated metabolism is a hallmark of cancer and recent evidence underlines that targeting tumor energetics may improve therapy response and patient outcome. Despite the general attitude of cancer cells to exploit the glycolytic pathway even in the presence of oxygen (aerobic glycolysis or Warburg effect), tumor metabolism is extremely plastic, and such ability to switch from glycolysis to oxidative phosphorylation (OxPhos) allows cancer cells to survive under hostile microenvironments. Recently, OxPhos has been related with malignant progression, chemo-resistance and metastasis. OxPhos is induced under extracellular acidosis, a well-known characteristic of most solid tumors, included melanoma.MethodsTo evaluate whether SOX2 modulation is correlated with metabolic changes under standard or acidic conditions, SOX2 was silenced and overexpressed in several melanoma cell lines. To demonstrate that SOX2 directly represses HIF1A expression we used chromatin immunoprecipitation (ChIP) and luciferase assay.ResultsIn A375-M6 melanoma cells, extracellular acidosis increases SOX2 expression, that sustains the oxidative cancer metabolism exploited under acidic conditions. By studying non-acidic SSM2c and 501-Mel melanoma cells (high- and very low-SOX2 expressing cells, respectively), we confirmed the metabolic role of SOX2, attributing SOX2-driven OxPhos reprogramming to HIF1 pathway disruption.ConclusionsSOX2 contributes to the acquisition of an aggressive oxidative tumor phenotype, endowed with enhanced drug resistance and metastatic ability.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available